Techniques: Species' finest blend - Humanized mouse models in inflammatory skin disease research

Trends in Pharmacological Sciences

Volumn 25, Issue 10, 2004, Pages 543-549

  Igney, Frederik H ^a   Asadullah, Khusru ^a   Zollner, Thomas M ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIPSORIASIS AGENT; ANTISENSE OLIGONUCLEOTIDE; BAYX 1005; CALCINEURIN INHIBITOR; CALCITRIOL; CLOBETASOL PROPIONATE; COLECALCIFEROL; CYCLOSPORIN A; CYTOKINE; DEXAMETHASONE; EFALIZUMAB; GLUCOCORTICOID; INTERLEUKIN 10; INTERLEUKIN 15 ANTIBODY; K 252A; LACTACYSTIN BETA LACTONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LYMPHOCYTE FUNCTION ASSOCIATED ANTIBODY 1; NERVE GROWTH FACTOR ANTIBODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEASOME INHIBITOR; SELECTIN ANTAGONIST; SOMATOMEDIN C; TROGLITAZONE; UNCLASSIFIED DRUG; WHEAT GERM AGGLUTININ;

ATOPIC DERMATITIS; CELL INFILTRATION; DELAYED HYPERSENSITIVITY; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; LYMPHOCYTE MIGRATION; MEDICAL RESEARCH; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; SKIN ALLERGY; SKIN DISEASE; SKIN INFLAMMATION; T LYMPHOCYTE;

ANIMALS; DERMATITIS; DISEASE MODELS, ANIMAL; HUMANS; MICE; RESEARCH DESIGN; SPECIES SPECIFICITY;

EID: 4544340336     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2004.08.004     Document Type: Review

References (61)

1. J. Mestas, and C.C. Hughes Of mice and not men: differences between mouse and human immunology J. Immunol. 172 2004 2731 2738
2. B.A. Croy Primer for non-immunologists on immune-deficient mice and their applications in research Comp. Med. 51 2001 300 313
3. The Jackson Laboratory Immunodeficient model selection: choosing a nude, scid or Rag1 strain JAX Communication 2 2000 1 4
4. P.H. Davis, and S.L. Stanley Jr Breaking the species barrier: use of SCID mouse-human chimeras for the study of human infectious diseases Cell. Microbiol. 5 2003 849 860
5. J.M. McCune Development and applications of the SCID-hu mouse model Semin. Immunol. 8 1996 187 196
6. W.J. Murphy The huPBL-SCID mouse as a means to examine human immune function in vivo Semin. Immunol. 8 1996 233 241
7. M.G. Roncarolo Human T- and B-cell functions in SCID-hu mice Semin. Immunol. 8 1996 207 213
8. J.M. Carballido Generation of primary antigen-specific human T- and B-cell responses in immunocompetent SCID-hu mice Nat. Med. 6 2000 103 106
9. E. Traggiai Development of a human adaptive immune system in cord blood cell-transplanted mice Science 304 2004 104 107
10. H.C. Yan Human/severe combined immunodeficient mouse chimeras. An experimental in vivo model system to study the regulation of human endothelial cell-leukocyte adhesion molecules J. Clin. Invest. 91 1993 986 996
11. J.S. Schechner Engraftment of a vascularized human skin equivalent FASEB J. 17 2003 2250 2256
12. L.S. Villadsen Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model J. Clin. Invest. 112 2003 1571 1580
13. P. Rizza First international workshop on human/SCID mouse models J. Biol. Regul. Homeost. Agents 15 2001 170 174
14. M.E. Reinders Proinflammatory functions of vascular endothelial growth factor in alloimmunity J. Clin. Invest. 112 2003 1655 1665
15. N.A. Turgeon Alloimmune injury and rejection of human skin grafts on human peripheral blood lymphocyte-reconstituted non-obese diabetic severe combined immunodeficient beta(2)-microglobulin-null mice Exp. Biol. Med. (Maywood) 228 2003 1096 1104
16. W.H. Boehncke The SCID-hu xenogeneic transplantation model: complex but telling Arch. Dermatol. Res. 291 1999 367 373
17. M.P. Schon The molecular basis of lymphocyte recruitment to the skin: clues for pathogenesis and selective therapies of inflammatory disorders J. Invest. Dermatol. 121 2003 951 962
18. D.D. Taub Chemokine-induced human lymphocyte infiltration and engraftment in huPBL-SCID mice Methods Enzymol. 287 1997 265 291
19. A.G. Murray Dermal microvascular injury in the human peripheral blood lymphocyte reconstituted-severe combined immunodeficient (HuPBL-SCID) mouse/skin allograft model is T cell mediated and inhibited by a combination of cyclosporine and rapamycin Am. J. Pathol. 153 1998 627 638
20. N.C. Kirkiles-Smith IL-11 protects human microvascular endothelium from alloinjury in vivo by induction of survivin expression J. Immunol. 172 2004 1391 1396
21. P. Sultan Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras Nat. Biotechnol. 15 1997 759 762
22. R. Kunstfeld MCP-1 and MIP-1alpha are most efficient in recruiting T cells into the skin in vivo J. Invest. Dermatol. 111 1998 1040 1044
23. O. Fahy Chemokine-induced cutaneous inflammatory cell infiltration in a model of Hu-PBMC-SCID mice grafted with human skin Am. J. Pathol. 158 2001 1053 1063
24. H.L. Spiegelberg Role of interleukin-4 in human immunoglobulin E formation in hu-PBL-SCID mice J. Clin. Invest. 93 1994 711 717
25. J. Pestel Human IgE in SCID mice reconstituted with peripheral blood mononuclear cells from Dermatophagoides pteronyssinus-sensitive patients J. Immunol. 153 1994 3804 3810
26. E.R. Jarman Deficient cytokine response of human allergen-specific T lymphocytes from humanized SCID mice and reconstitution by professional antigen-presenting cells J. Allergy Clin. Immunol. 105 2000 967 974
27. U. Herz A human-SCID mouse model for allergic immune response bacterial superantigen enhances skin inflammation and suppresses IgE production J. Invest. Dermatol. 110 1998 224 231
28. U. Herz Increased airway responsiveness, allergy-type-I skin responses and systemic anaphylaxis in a humanized-severe combined immuno-deficiency mouse model Clin. Exp. Allergy. 34 2004 478 487
29. T. Biedermann Targeting CLA/E-selectin interactions prevents CCR4-mediated recruitment of human Th2 memory cells to human skin in vivo Eur. J. Immunol. 32 2002 3171 3180
30. J.M. Carballido The SCID-hu Skin mouse as a model to investigate selective chemokine mediated homing of human T-lymphocytes to the skin in vivo J. Immunol. Methods. 273 2003 125 135
31. S. Senechal CCR3-Blocking Antibody Inhibits Allergen-Induced Eosinophil Recruitment in Human Skin Xenografts from Allergic Patients Lab. Invest. 82 2002 929 939
32. Zollner, T.M. et al. (2005) Acute and chronic models of allergic contact dermatitis: advantages and limitations. In Animal Models of T Cell-mediated Skin Diseases (Zollner, T.M. et al., eds) (Vol. 50), pp. 255-276, Ernst Schering Research Foundation Workshop, Springer
33. N. Rosenblatt-Velin Transformed and nontransformed human T lymphocytes migrate to skin in a chimeric human skin/SCID mouse model J. Invest. Dermatol. 109 1997 744 750
34. P. Petzelbauer Human delayed-type hypersensitivity reaction in a SCID mouse engrafted with human T cells and autologous skin J. Invest. Dermatol. 107 1996 576 581
35. A. Tsicopoulos Tuberculin-induced delayed-type hypersensitivity reaction in a model of hu-PBMC-SCID mice grafted with autologous skin Am. J. Pathol. 152 1998 1681 1688
36. E. Jankowska-Gan Human liver allograft acceptance and the "tolerance assay". II. Donor HLA-A, -B but not DR antigens are able to trigger regulation of DTH Hum. Immunol. 63 2002 862 870
37. S.P. Raychaudhuri Severe combined immunodeficiency mouse-human skin chimeras: a unique animal model for the study of psoriasis and cutaneous inflammation Br. J. Dermatol. 144 2001 931 939
38. A. Gilhar T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice J. Invest. Dermatol. 109 1997 283 288
39. T. Yamamoto Repeated subcutaneous injection of staphylococcal enterotoxin B-stimulated lymphocytes retains epidermal thickness of psoriatic skin-graft onto severe combined immunodeficient mice J. Dermatol. Sci. 17 1998 8 14
40. Boehncke, W.H. (2005) The psoriasis SCID mouse model - a tool for drug discovery? In Animal Models of T Cell-mediated Skin Diseases (Zollner, T.M. et al., eds) (Vol. 50), pp. 213-234, Ernst Schering Research Foundation Workshop, Springer
41. T.M. Zollner Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model J. Clin. Invest. 109 2002 671 679
42. M.P. Schon Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation Nat. Med. 8 2002 366 372
43. M. Zeigler Anti-CD11a ameliorates disease in the human psoriatic skin-scid mouse transplant model: comparison of antibody to cd11a with cyclosporin a and clobetasol propionate Lab. Invest. 81 2001 1253 1261
44. S.P. Raychaudhuri K252a, a high-affinity nerve growth factor receptor blocker, improves psoriasis: an in vivo study using the severe combined immunodeficient mouse-human skin model J. Invest. Dermatol. 122 2004 812 819
45. C.J. Wraight Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides Nat. Biotechnol. 18 2000 521 526
46. C.N. Ellis Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation Arch. Dermatol. 136 2000 609 616
47. W.H. Boehncke The SCID-hu xenogeneic transplantation model allows screening of anti- psoriatic drugs Arch. Dermatol. Res. 291 1999 104 106
48. T.N. Dam 1alpha,25-dihydroxycholecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice J. Invest. Dermatol. 113 1999 1082 1089
49. W.H. Boehncke Pulling the trigger on psoriasis Nature 379 1996 777
50. B.J. Nickoloff, and T. Wrone-Smith Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis Am. J. Pathol. 155 1999 145 158
51. A. Gilhar Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes: induction of psoriasis by cells with natural killer receptors J. Invest. Dermatol. 119 2002 384 391
52. O. Boyman Spontaneous development of psoriasis in a new animal model shows an essential role for resident t cells and tumor necrosis factor-{alpha} J. Exp. Med. 199 2004 731 736
53. A. Gilhar Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice J. Clin. Invest. 101 1998 62 67
54. R.S. Kalish, and A. Gilhar Alopecia areata: autoimmunity-the evidence is compelling J. Investig. Dermatol. Symp. Proc. 8 2003 164 167
55. A. Gilhar Mediation of alopecia areata by cooperation between CD4+ and CD8+ T lymphocytes: transfer to human scalp explants on Prkdc(scid) mice Arch. Dermatol. 138 2002 916 922
56. A. Gilhar Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(scid) mice J. Invest. Dermatol. 117 2001 1357 1362
57. A. Gilhar Transfer of alopecia areata in the human scalp graft/Prkdc(scid) (SCID) mouse system is characterized by a TH1 response Clin. Immunol. 106 2003 181 187
58. N. Yamanaka Engraftment of tonsillar mononuclear cells in human skin/SCID mouse chimera-validation of a novel xenogeneic transplantation model for autoimmune diseases Microbiol. Immunol. 45 2001 507 514
59. D. Zillikens Antibodies to desmogleins 1 and 3, but not to BP180, induce blisters in human skin grafted onto SCID mice J. Pathol. 193 2001 117 124
60. S. Ortiz-Urda The plant lectin wheat germ agglutinin inhibits the binding of pemphigus foliaceus autoantibodies to desmoglein 1 in a majority of patients and prevents pathomechanisms of pemphigus foliaceus in vitro and in vivo J. Immunol. 171 2003 6244 6250
61. C.J. Gruss Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID mice J. Invest. Dermatol. 120 2003 683 692